What is BioMarin Pharmaceuticals's revenue?

BioMarin Pharmaceuticals (BMRN) generated $3.2B in revenue over the trailing twelve months, up 9.9% year over year.

Is BioMarin Pharmaceuticals profitable?

BioMarin Pharmaceuticals reported $501.0M in net income over the trailing twelve months, a 16.8% net margin.

What are BioMarin Pharmaceuticals's profit margins?

Gross margin is 76.5% and operating margin is 19.9%, with a 16.8% net margin.

What is BioMarin Pharmaceuticals's earnings per share?

BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $2.56.

Where does BioMarin Pharmaceuticals's income statement data come from?

Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

BioMarin Pharmaceuticals BMRN Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$3.22B+12.9%	$2.85B+18.0%	$2.42B+15.4%	$2.1B+13.5%
Total cost of revenue	$717.44M+23.6%	$580.24M+9.1%	$532.06M+5.8%	$503.02M+6.9%
Gross profit	$2.5B+10.1%	$2.27B+20.5%	$1.89B+18.5%	$1.59B+15.8%
Gross margin	77.7%-1.9pp	79.7%+1.7pp	78%+2.0pp	76%+1.5pp
Research and development	$921.93M+23.4%	$747.18M+0.1%	$746.77M+15.0%	$649.61M+3.3%
Selling, general and administrative	$1.15B+14.3%	$1.01B+13.1%	$892.41M+8.4%	$823.24M+8.4%
Compensation and benefits	——	——	——	——
Depreciation and amortization	$79.56M-17.5%	$96.43M-7.6%	$104.39M+2.4%	$101.97M-5.6%
Impairment charges	——	——	——	——
Other operating expenses	$9M+293%	-$4.67M+87.8%	-$38.22M-184%	-$13.46M-214%
Total costs & expenses	$2.81B+18.7%	$2.37B+6.1%	$2.23B+15.4%	$1.94B+0.3%
Operating income	——	$484.21M+161%	$185.77M+6.7%	$174.06M+311%
Interest expense	$10.9M-14.0%	$12.67M-26.9%	$17.34M+8.5%	$15.97M+4.1%
Interest income	$74.9M0.0%	$74.88M+28.4%	$58.34M+223%	$18.03M+72.0%
Other income (expense), net	——	——	——	——
Income before income taxes	$509.63M-5.9%	$541.76M+187%	$188.56M—	——
Income tax expense	$133.58M+16.3%	$114.9M+423%	$21.97M—	——
Net income	——	$426.86M+155%	$167.65M+18.2%	$141.81M+321%
Diluted earnings per share	——	$2.21+154%	$0.87+16.0%	$0.75+308%
Basic earnings per share	——	$2.25+153%	$0.89+15.6%	$0.77+320%
Weighted-average shares, diluted	783M-1.3%	793.6M+2.8%	772.1M+2.0%	756.9M+2.9%
Weighted-average shares, basic	766.7M+1.0%	759.4M+1.2%	750.7M+1.4%	740.1M+1.3%
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——
Pre-tax stock-based compensation cost	——	——	——	——
Amortization Of Debt Discount Premium	——	——	——	——
Amortization Of Financing Costs	——	——	——	——
Amortization Of Financing Costs And Discounts	$2.62M-21.9%	$3.36M-19.8%	$4.19M+1.7%	$4.12M-0.7%
Amortization of capitalized software and acquired intangible assets	$19.39M-55.2%	$43.26M-30.5%	$62.21M-7.4%	$67.19M—
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——
Accounts payable and accrued liabilities related to fixed assets	——	$3.75M-63.5%	$10.28M—	——
Accounts payable and accrued liabilities related to intangible assets	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——
Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	——	——
Deferred taxes	——	$56.1M+221%	-$46.23M+11.2%	-$52.09M-234%
Depreciation	——	——	——	——
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	——	——	——	——
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	——	——	——	——
Income taxes paid	$96.21M+68.0%	$57.27M-21.9%	$73.31M+34.8%	$54.37M+200%
Accounts payable and other current liabilities	——	——	$68.85M—	——
Increase (Decrease) in Accounts Receivable	——	——	$204.33M—	——
Increase (Decrease) in Inventories	$116.93M—	——	$157.06M+130%	$68.26M+94.7%
Increase (Decrease) in Other Current Assets	-$8.89M—	——	——	-$7.82M—
Increase (decrease) in other assets	$38.57M-47.7%	$73.7M+137%	$31.15M+56.9%	$19.86M+201%
Other liabilities	——	$14.76M-37.4%	$23.59M+240%	$6.93M—
Interest expense, net of amounts capitalized	——	——	——	——
After tax effect of debt interest	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$45.55M—	——	——	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$414.24M—	——	——	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$827.99M+44.5%	$572.84M+260%	$159.26M-9.5%	$175.9M-42.2%
Number of operating segments	——	——	——	——
Number of reportable segments	——	——	——	——
Oci Before Reclassifications Before Tax Attributable To Parent	——	——	——	——
Other comprehensive income/(loss)	——	——	——	——
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent	——	——	——	——
Other Noncash Income (Expense)	$4.63M+123%	-$20.14M-5,616%	$365K-82.1%	$2.04M—
Other income, net	$9M+293%	-$4.67M+87.8%	-$38.22M-184%	-$13.46M-214%
Payment for (Proceeds from) Other Investing Activity	——	-$1.14M—	——	——
Payments of Debt Issuance Costs	——	——	——	——
Payment, Tax Withholding, Share-Based Payment Arrangement	$55.97M-27.8%	$77.56M+1.6%	$76.32M+40.6%	$54.28M+18.5%
Payments to Acquire Investments	$355.88M-13.3%	$410.25M-52.8%	$868.5M+42.0%	$611.81M—
Payments to Acquire Property, Plant, and Equipment	$103.04M+20.6%	$85.42M-11.7%	$96.69M-20.1%	$120.96M+26.6%
Issuance of debt	——	——	——	——
Proceeds from disposition of marketable securities and other investments	$337.8M-46.6%	$633.02M-26.8%	$864.86M+39.5%	$620M-10.3%
Reclassification from AOCI, Current Period, before Tax, Attributable to Parent	——	——	——	——
Revenue From Contract With Customer Excluding Assessed Tax	$3.22B+12.9%	$2.85B+18.0%	$2.42B+15.4%	$2.1B+13.5%
Stock-based compensation	$181.41M-10.0%	$201.57M-2.7%	$207.1M+5.5%	$196.31M-0.5%
EBIT	$456.87M-5.6%	$484.21M+161%	$185.77M+6.7%	$174.06M+311%
EBITDA	$536.42M-7.6%	$580.64M+100%	$290.16M+5.1%	$276.03M+974%
EBITDA	$536.42M-7.6%	$580.64M+100%	$290.16M+5.1%	$276.03M+974%
EBITDA margin	16.7%-3.7pp	20.3%+8.4pp	12%-1.2pp	13.2%+11.8pp
EBIT	$456.87M-5.6%	$484.21M+161%	$185.77M+6.7%	$174.06M+311%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about BioMarin Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioMarin Pharmaceuticals's revenue?: BioMarin Pharmaceuticals (BMRN) generated $3.2B in revenue over the trailing twelve months, up 9.9% year over year.
Is BioMarin Pharmaceuticals profitable?: BioMarin Pharmaceuticals reported $501.0M in net income over the trailing twelve months, a 16.8% net margin.
What are BioMarin Pharmaceuticals's profit margins?: Gross margin is 76.5% and operating margin is 19.9%, with a 16.8% net margin.
What is BioMarin Pharmaceuticals's earnings per share?: BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $2.56.
Where does BioMarin Pharmaceuticals's income statement data come from?: Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.